← Back to Home

Breaching Cancer Cells’ Defenses Through Telomere Damage: MAIA Doses First U.S. Patient in Phase 2 Lung Cancer Trial

Ateganosine aims to damage cancer cell telomeres before subsequent immunotherapy, seeking a path forward for lung cancer patients whose existing treatments have failed. Dosing the first U.S. patient marks another step for the research, but whether this strategy can deliver durable efficacy remains a question for clinical data.

By SURL BioNews

When lung cancer continues to progress after immunotherapy and chemotherapy, choosing the next treatment becomes more difficult. One study is targeting telomeres at the ends of chromosomes, hoping to trigger a renewed immune attack by disrupting cancer cells’ survival mechanisms. MAIA Biotechnology announced on September 16, 2026, that the first U.S. patient had been dosed in its Phase 2 THIO-101 expansion trial, which is evaluating the potential of the investigational drug ateganosine as a third-line treatment for non-small cell lung cancer.

This development followed clearance by the U.S. Food and Drug Administration (FDA) of an amended Investigational New Drug (IND) application; according to the company, the amendments concerned improvements in manufacturing capacity and efficiency. The U.S. study is supported by a $2.3 million grant from the U.S. National Institutes of Health (NIH), and three trial sites have been activated. These conditions allow the research to advance, but do not mean that regulators have endorsed the drug’s efficacy.

Ateganosine, also known as THIO or 6-thio-dG, is a modified nucleoside. Its development is based on using telomerase’s involvement in telomere maintenance to induce telomeric DNA damage. Telomeres serve as protective structures at the ends of chromosomes. According to the mechanism proposed by the company, this damage may not only cause cancer cell death but also activate immune signaling, making tumors more susceptible to attack by the immune system.

THIO-101 therefore administers ateganosine first, followed by the immune checkpoint inhibitor cemiplimab. The study seeks to test whether inducing telomere damage first can enhance or prolong the subsequent immune response. This expansion focuses on patients with advanced disease who are entering third-line treatment after progression following prior immune checkpoint inhibitor therapy and chemotherapy.

THIO-101 as a whole is a multicenter, open-label, Phase 2 dose-finding trial. In addition to safety and tolerability, it uses overall response rate as its primary clinical efficacy measure, assessing how many patients achieve tumor shrinkage that meets predefined criteria. Response rates can provide evidence of antitumor activity, but cannot alone establish whether patients live longer or how long treatment benefits last.

The company stated in its announcement that eight patients in the trial’s earlier Parts A and B had survived for more than 24 months. However, the announcement did not provide the patient denominator, comparator results, or detailed safety data needed to fully interpret this signal, so it cannot support an inference of a survival benefit for the overall patient population. The content published on the company’s website and by GlobeNewswire also comes from the same press release and does not constitute two independent bodies of evidence.

The significance of dosing the first U.S. patient is that this strategy of telomere damage followed by immunotherapy has begun generating research data in U.S. participants. Its clinical value will ultimately depend on whether tumor responses are sustained, whether toxicity is acceptable, and whether more complete research can demonstrate patient benefit. A single dosing milestone cannot yet answer these questions.

References

  1. GlobeNewswire
  2. MAIA Biotechnology, Inc.